





Medical NBC Briefing Series Medical NBC Aspects of Dengue Fever









Purpose

- •This presentation is part of a series developed by the Medical NBC Staff at The U.S. Army Office of The Surgeon General.
- •The information presented addresses medical issues, both operational and clinical, of various NBC agents.
- •These presentations were developed for the medical NBC officer to use in briefing either medical or maneuver commanders.
- •Information in the presentations includes physical data of the agent, signs and symptoms, means of dispersion, treatment for the agent, medical resources required, issues about investigational new drugs or vaccines, and epidemiolc

 Office of the Surgeon General
- •Notes pag

nce.

for the Army





Outline

- Background
- Battlefield Response
- Medical Response
- Command and Cont
- Summary
- References







Background

- Disease Background
- Disease Course Summary

Signs and Symptoms

- Diagnosis
- Treatment
- Current Situation
- Weaponization




DASG-HCF 4 18 Jul





Disease Background

- Virus (arbovirus genus -Flavivirus)
- Various forms of the disease to include dengue hemorrhagic fever and dengue shock syndrome
- Primarily a disease of the tropics
- Mainly transmitted by mosquito







Dengue Disease Course Summary in Untreated Individuals

Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
EXPOSUR			High	fever, he	adache, et	c.
E	Incuba	tion 3-5	lasti	ng 2 to 7	days	
Day 8	Days Day 9	Day 10	Day 11	Day 12	Day 13	Day 14
	er, headad g 2 to 7 d		untrea	ity rate fo ted DHF o as 20%		
Day 15	Day 16	Day 17	Day 18	Day 19	Day 20	Day 21
Day 22	Day 23	Day 24	Day 25	Day 26	Day 27	Day 28


DASG-HCF 6





Signs and Symptoms

- Fever lasting for 2 to 7 days and as high as 104 to 106 °F.
- Severe headache, muscle pain, joint pain, conjunctivitis, severe orbital pain, backache, anorexia, and gastrointestinal disturbances.
- Other symptoms may include a rash, minute reddish/purplish spots, nose bleeds, or bleeding gums.







Diagnosis

 Sudden onset of fever, severe headache, muscle and joint pain, accompanied occasionally by a rash and hemorrhagic manifestations

Detection of anti-dengue









Treatment

Supportive care

- Keep patient hydrated to prevent shock
- Hospitalization of patients with advanced symptoms

For complete treatment protocol refer to the following reference:


Dengue hemorrhagic fever:
 diagnosis, treatment, prevention
 and control. 2nd edition. Geneva
 : World Health Organization.
 1997.







Current Situation








Weaponization

Aerosolization

- Highly infectious via aerosol
- Delivery systems can be simple such a spray systems or stationary munitions

Vectors

 Naturally spread by the Aedes aegypti mosquito







Battlefield Response to Dengue Fever

Detect

- Environmental dete
- Clinical detection
- Medical surveillance

Protect

- Vaccination
- Individual protection
- Collective protection








Detection

- Possible methods of detection
 - Detection of agent in the environ
 - Clinical (differential diagnosis)
 - Medical surveillance (coordination enhances detection capability)
- Diagnosis of dengue is not presumptive of a BW attack. The disease may be endemic to the area.









Detection of Agent in the Environment

- Biological Smart
 Tickets
- Enzyme Linked Immunosorbant Assay (ELISA) (Fielded with the 520th TAML)
- Polymerase Chain
 Reaction (PCR) (Fielded







Detection of Agent in the Environment (cont.)

- M31E1 Biological Integrated Detection System (BIDS)
- Interim Biological Agent Detector (IBAD)










Clinical Detection





Clinical presentation

 Sudden presentation of fever, severe headache, muscle and joint pain, accompanied occasionally by a rash and hemorrhagic manifestations

Laboratory confirmation

- Division medical assets may lack lab equipment to conduct test to determine dengue
- Specimen must be sent to theater level or CONUS lab
- Contact lab prior to collection or preparation in order to assure proper methods are utilized



Detection by Medical Surveillance

Patient Summary Report 20th INF (L) DIV	20	Prom: Division Medical Operations Center (DMOC)		MA D DIVISION	RYLAND ARMY ISCOM 29 th Infan I MEDICAL OPE	NATIONAL GUA utry Division (Ligi RATION CENTE	ARD ht) R (DMOC)	\$			
To: Division Surgeon Date Time Group: From: 121200RUN99 To: 202400RUN99 To: 202400RUN99	To: Division Surgeon Date Time Group: From: 12/12/00/RJUN99 To: 2024/00/RJUN99 PATIENTS	To: Division Surgeon Date Time Group: From: 121200RJUN99 To: 20240RJUN99 PATIENTS Disease Neuropsychiatric Total Street St	To: Division Surgeon Date Time Group: From: 121200RJUN99 To: 20240RJUN99 PATIENTS Disease Neuropsychiatric Total Street St	To: Division Surgeon Date Time Group: From: 121200RJUN99 To: 20240RJUN99 PATIENTS Disease Neuropsychiatric Total Street St	To: Division Surgeon Date Time Group: From: 121200RJUN99 To: 20240RJUN99 PATIENTS Disease Neuropsychiatric Total Street St			Patient Sum 29 th INF	mary Report (L) DIV		
Date Time Group: From: 121200EJUN99 To: 202460EJUN99	Date Time Group: From: 121200RJUN99 To: 202460RJUN99	Date Time Group: From: 121200RJUN99 To: 202460RJUN99	Date Time Group: From: 121200RJUN99 To: 202460RJUN99	Date Time Group: From: 121200RJUN99 To: 202460RJUN99	Date Time Group: From: 121200RJUN99 To: 202460RJUN99		Division Medical	Operations Center	(DMOC)		
Nation WIA NBI Disease Neuropeocharie Total	Nation WIA NBI Disease Neuroperchainte Total	Nation WIA NBI Disease Neuroperchainte Total	Nation WIA NBI Disease Neuroperchainte Total	Nation WIA NBI Disease Neuroperchainte Total	Nation WIA NBI Disease Neuroperchainte Total		: From:	121200RJUN99			
US	US	US	US	US	US	PATIENTS					
Allied	Allied	Allied	Allied	Allied	Allied						
DISPOSITION	DISPOSITION	DISPOSITION	DISPOSITION	DISPOSITION	DISPOSITION						
Return to daily	Return to daily	Return to daily	Return to daily	Return to daily	Return to daily						
						Evacuated by gro Expired en route	ound				1 0

Clues in the daily medical disposition reports

- Large numbers of individuals presenting at the same time without natural vectors present.
- Individuals presenting with high fevers, headaches, muscle and joint pain

17 Dengue fever not endehicun





Vaccination

No dengue vaccine is available







Individual Protection

- Mask and BDO with gloves and boots
- Standard uniform clothing affords good protection against dermal exposure to biological agents
- Casualties unable to wear MOPP should be handled in casualty wraps





Collective Protection

- Hardened or unhardened shelter equipped with an air filtration unit providing overpressure
- Standard universal precautions should be employed as individuals are brought inside the collective protection units
- Dengue is communicable from person to person through vectors
- Contaminated articles can be decontaminated using 0.05% hypochlorite solution







Medical Response to Dengue Fever

- Triage and Evacuation
- Infection Control
- Resource Requirements







Triage and Evacuation

Triage

- Priorities based on severity of symptoms
- Respiratory support, ICU needs, and quarantine facilities will increase priorities

Evacuation

- Standard infection control precautions during transport
- May consider treatment in place for a mass casualty situation
- Evacuation of patients will be METT-T dependent


DASG-HCF

18 Jui





Evacuation or Quarantine



Evacuation


- Dengue patients may not RTD in the normal theater evacuation policy of 15 days
- Strict interpretation of the doctrine calls for evacuation

Quarantine

- Limit spread of the virus
- Unlike smallpox, dengue is already endemic to various parts of the world

• Guidance

- Before evacuating large numbers of patients suspected of dengue, seek guidance from CINC and MTF







Infection Control

 No reported cases of direct person-toperson transmission

 Transmitted through vectors (mosquitoes)

Protect against vectors

 Use standard universal precautions during treatment





DASG-HCF

18 Ju




DASG-HCF



Resource Requirements

- Evacuation assets
- Treatment facilities
- Supportive therapies
 - Vigorous IV therapy
- Intensive care facilities for severely compromised patients
- Vector control
- Possibility for intheater treatment of large numbers of patients





Infection control

25





Command and Control

Intelligence

 Medical surveillance and intelligence reports are key to keep the Command alert to the situation

Evacuation of the sick

Maneuver

- Quarantine or isolation is required of symptomatic patients

Manpower

 Many soldiers may be affected by aerosol dissemination in a short period of time

Logistics

- Additional Class VIII materials will be required and evacuation routes to Echelon III will be heavily utilized
- Specialized evacuation assets may be required





- May vary from person to person
- Psychological Operations
 - Rumors, panic, misinformation
 - Soldiers may isolate themselves in fear of disease spread

Countermeasures

- LEADERSHIP is responsible for countering psychological impacts through education and training of the soldiers
- Implementation of defensive measures such as crisis stress management teams

DASG-HCF 27 18 Ju



Summary

- Dengue fever is endemic through large parts of the world and is transmitted by vectors.
- The possibility for weaponization exists.
- Detection may not occur until after exposure when patients are reported.
- Command decisions that will be required upon detection of dengue:
 - Evacuation or treatment in-theater for large numbers of patients?
 - Evacuation: Many patients will be presenting at one time. Methods of evacuation?
 - Treatment: Procurement of additional equipment 8 Jun





References

- Biological and Chemical Warfare Online Repository and Technical Holding System (BACWORTH), Version 3.0. Battelle Memorial Institute, 1997.
- Biological Warfare and Its Cutaneous Manifestations (in Electronic Textbook of Dermatology), T. W. McGovern and G. W. Christopher. Found at www.telemedicine.org/ BioWar/biologic.htm.
- Centers for Disease Control and Prevention website: www.cdc.gov/ncidod/dvbid/dhspot98. htm.
- Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition. Geneva: World Health Organization. 1997. Found at www.who.int/ctd/dengue/whodocs.htm
- Department of Defense, Chemical and Biological Defense Program, Annual Report to Congress, March 2000.
- Department of the Army. FM 8-10-6: *Medical Evacuation in a Theater of Operations*. April 2000.
- Department of the Army. FM 8-10: Health Service Support In A Theater of Operations. March 1991.
- Department of the Army. FM 8-284: Treatment of Biological Warfare Agent Casualties. July 2000.
- Medical Aspects of Chemical and Biological Warfare (in Textbook of Military Medicine Series Part I: Warfare, Weaponry, and the Casualty), edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz. Washington, DC: TMM Publications, 1997.

DASG-HCF







Battelle Memorial Institute created this presentation for the U.S. **Army Office of the** Surgeon General under the Chemical Biological **Information Analysis** Center Task 009, Delivery Number 0018.

DASG-HCF 30